NASH: Wall Street’s Forgotten Mega Blockbuster Indication

NASH rose to prominence in the investing world during this period for four key reasons:

There are no FDA-approved medications to directly treat NASH.

NASH incidence rates are skyrocketing across the globe, thanks to the out-of-control obesity and diabetes epidemics.

Wall Street estimated that this untapped drug market could generate annual sales in excess of $35 billion per year.

This four-year period saw a handful of drugmakers make significant progress in the clinic with their lead NASH candidates.